RMC No. 127-2021: Publishes the full text of letter from the Food and Drug Administration with the subject “Response to Query on the List of VAT-Exempt Products”

Summary

RMC No. 127-2021 publishes the full text of an FDA letter from Director General Rolando Enrique D. Domingo titled Response to Query on the List of VAT-Exempt Products.

Key points

1. Liraglutide 6mg/mL. The letter says Liraglutide 6mg/mL Solution for Injection (SC) is VAT-exempt only if its use falls under the management of diabetes.
2. Saxenda brand. Liraglutide 6mg/mL Solution for Injection (SC) under the brand name Saxenda is for management of overweight and obesity. That use does not fall under the identified diseases covered by the TRAIN Law and the CREATE Act.

Summary by Tax Resources PH. It is not a substitute for the full text of the issuance or professional advice.